| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 89.77 | -8 |
| Intrinsic value (DCF) | 45.42 | -54 |
| Graham-Dodd Method | 35.09 | -64 |
| Graham Formula | 59.33 | -39 |
bioMérieux S.A. (BIM.PA) is a global leader in in vitro diagnostics (IVD), specializing in infectious disease detection, cardiovascular pathologies, and cancer diagnostics. Headquartered in Marcy l'Etoile, France, the company serves clinical laboratories, hospitals, and industrial sectors, including food, pharmaceutical, and cosmetics testing. Founded in 1963 and a subsidiary of Institut Mérieux SA, bioMérieux operates across the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company’s innovative diagnostic systems enhance patient care by enabling rapid and accurate disease identification. With a strong focus on microbiological testing, bioMérieux plays a critical role in public health and industrial safety. Its diversified revenue streams and commitment to R&D position it as a key player in the growing IVD market, which is driven by increasing demand for precision medicine and infectious disease management.
bioMérieux presents a compelling investment case due to its leadership in the high-growth in vitro diagnostics (IVD) sector, supported by a diversified product portfolio and global reach. The company’s strong financials, including €4.0B in revenue and €432M net income (FY 2024), reflect steady profitability. Its low beta (0.505) suggests resilience to market volatility, appealing to risk-averse investors. However, reliance on infectious disease testing could expose revenue to cyclical demand fluctuations. The dividend yield (~0.85/share) is modest, making growth-oriented investors the primary target. Expansion in emerging markets and ongoing R&D investments could drive future upside, but regulatory hurdles and competition from larger IVD players remain key risks.
bioMérieux holds a competitive edge in niche segments like microbiology and infectious disease diagnostics, where its automated systems (e.g., VITEK® and BACT/ALERT®) are industry standards. Its subsidiary status under Institut Mérieux provides stability and long-term R&D funding. However, it faces intense competition from global IVD giants like Roche and Abbott, which boast broader portfolios and larger sales networks. bioMérieux’s focus on industrial applications (food/pharma testing) differentiates it but limits exposure to high-growth areas like molecular diagnostics. Geographically, its strong European presence is a double-edged sword—providing steady revenue but lagging in the faster-growing U.S. and Asian markets. The company’s mid-market cap (~€13.7B) means it lacks the scale of top rivals but can pivot more agilely to emerging trends like antimicrobial resistance testing.